Two Sigma Investments’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-8,800
Closed -$3.32M 2991
2021
Q4
$3.32M Buy
8,800
+6,300
+252% +$2.45M 0.01% 1498
2021
Q3
$1.03M Buy
+2,500
New +$1.04M ﹤0.01% 2591
2021
Q2
Sell
-4,500
Closed -$1.3M 4118
2021
Q1
$1.3M Buy
+4,500
New +$1.25M ﹤0.01% 2071

Other funds holding CRL

Two Sigma Investments's CRL Position: Q1 2026 in Review

Two Sigma Investments reduced its Charles River Laboratories (CRL) stake by 27% in Q1 2026, selling an estimated $1.39M and leaving 20,623 shares worth $3.56M. The position accounts for ﹤0.01% of the portfolio, ranked #2293.

Two Sigma Investments first reported a position in CRL in Q2 2013 and has held it in 44 quarters since. The position peaked at $74.1M in Q1 2022. 558 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Two Sigma Investments held 20,623 shares of Charles River Laboratories worth $3.56M as of Q1 2026.
  • Two Sigma Investments sold 7,482 Charles River Laboratories shares in Q1 2026, an estimated $1.39M.
  • Charles River Laboratories made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #2293 holding.
  • Two Sigma Investments first reported a position in Charles River Laboratories in Q2 2013 and has held it in 44 quarters since.
  • Two Sigma Investments's Charles River Laboratories position peaked at $74.1M in Q1 2022.
  • 558 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.